Yesterday’s approval comes months after Novartis turned its back on tislelizumab, returning global rights to BeiGene. The companies signed a collaboration contract for tislelizumab in January 2021, but ran into several regulatory roadblocks.
Tag Archive for: tislelizumab
Beigene said on Tuesday it would regain rights to develop and sell its cancer drug globally from Swiss drugmaker Novartis after the companies mutually decided to end their licensing deal.
Chinese drug developer BeiGene said on Thursday its experimental drug helped extend lives of patients with a type of gastric cancer in a late-stage trial.
